The theory of homogeny of liver and kidney in the treatment of kidney and liver fibrosis

Ping Li; Hao-jun Zhang; Liu-tao Zheng

doi:10.1007/s11655-012-1063-5

Your Location：

Home >

Browse articles >

The theory of homogeny of liver and kidney in the treatment of kidney and liver fibrosis

OriginalPaper | Updated：2021-08-27

- The theory of homogeny of liver and kidney in the treatment of kidney and liver fibrosis
- The theory of homogeny of liver and kidney in the treatment of kidney and liver fibrosis
- 中国结合医学杂志（英文版） 2012年18卷第4期页码：250-252
- Affiliations：
  
  Department of Pharmacology, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital,Beijing,China
- Author bio：
- Funds：
  
  Supported by Program of International S&T Cooperation Project (No. 2011DFA31860)
- DOI：10.1007/s11655-012-1063-5
  中图分类号：
- 纸质出版日期：2012，
  
  网络出版日期：2012-3-30，
Scan for full text
Li, P., Zhang, Hj. & Zheng, Lt. The theory of homogeny of liver and kidney in the treatment of kidney and liver fibrosis., Chin. J. Integr. Med. 18, 250–252 (2012). https://doi.org/10.1007/s11655-012-1063-5

Ping Li, Hao-jun Zhang, Liu-tao Zheng. The theory of homogeny of liver and kidney in the treatment of kidney and liver fibrosis[J]. Chinese Journal of Integrative Medicine, 2012,18(4):250-252.
Li, P., Zhang, Hj. & Zheng, Lt. The theory of homogeny of liver and kidney in the treatment of kidney and liver fibrosis., Chin. J. Integr. Med. 18, 250–252 (2012). https://doi.org/10.1007/s11655-012-1063-5 DOI：

Ping Li, Hao-jun Zhang, Liu-tao Zheng. The theory of homogeny of liver and kidney in the treatment of kidney and liver fibrosis[J]. Chinese Journal of Integrative Medicine, 2012,18(4):250-252. DOI： 10.1007/s11655-012-1063-5.

摘要

Chronic kidney disease (CKD) and chronic liver disease are both very harmful to human health almost all over the world

which lead to the fibrosis of the two organs ultimately. Currently

there are few satisfactory therapeutic methods in treating the two diseases. Some research works from Chinese medicine and Western medicine were done in the area recently

the results showed that kidney and liver fibrosis shared similar biological signals and events such as epithelial-mesenchymal transition (EMT) and transforming growth factor β 1

the same herbal mesenchymal medicine exhibited significantly improving effects on both liver fibrosis and kidney fibrosis by involving similar mechanism. This coincides with the theory of homogeny of Liver (Gan) and Kidney (Shen) of Chinese medicine. It would provides new clues in exploring the treatment of liver fibrosis and kidney fibrosis.

Abstract

Chronic kidney disease (CKD) and chronic liver disease are both very harmful to human health almost all over the world

which lead to the fibrosis of the two organs ultimately. Currently

there are few satisfactory therapeutic methods in treating the two diseases. Some research works from Chinese medicine and Western medicine were done in the area recently

the results showed that kidney and liver fibrosis shared similar biological signals and events such as epithelial-mesenchymal transition (EMT) and transforming growth factor β 1

关键词

homogenyliverkidneyfibrosissaikosaponin-d

Keywords

homogenyliverkidneyfibrosissaikosaponin-d

references

Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011;25:195–206.

Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. Profibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 2007;46:1064–1074.

Subeq YM, Ke CY, Lin NT, Lee CJ, Chiu YH, Hsu BG. Valsartan decreases TGF-beta1 production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in rats. Cytokine 2011;53:223–230.

Sun L, Zhang D, Liu F, Xiang X, Ling G, Xiao L, et al. Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. J Pathol 2011;225:364–377.

Meng XM, Huang XR, Chung AC, Qin W, Shao X, Igarashi P, et al. Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J Am Soc Nephrol 2010;21:1477–1487.

Zhang H, Ho YF, Che CT, Lin ZX, Leung C, Chan LS. Topical herbal application as an adjuvant treatment for chronic kidney disease—a systematic review of randomized controlled clinical trials. J Advanced Nursing 2012. Epub ahead of print.

Li P, Gong Y, Zu N, Li Y, Wang B, Shimizu F. Therapeutic mechanism of saikosaponin-d in anti-Thy1 mAb 1-22-3-induced rat model of glomerulonephritis. Nephron Exp Nephrol 2005;101:e111–118.

Zu N, Li P, Li N, Choy P, Gong Y. Mechanism of saikosaponin-d in the regulation of rat mesangial cell proliferation and synthesis of extracellular matrix proteins. Biochem Cell Biol 2007;85:169–174.

Fan J, Li X, Li P, Li N, Wang T, Shen H, et al. Saikosaponin-d attenuates the development of liver fibrosis by preventing hepatocyte injury. Biochem Cell Biol 2007;85:189–195.

Li P, Yan J, Sun Y, Burczynski FJ, Gong Y. Chinese herbal formula Qilong-Lishui granule improves puromycin aminonucleoside-induced renal injury through regulation of bone morphogenetic proteins. Nephrology (Carlton) 2007;12:466–473.

FULL TEXT LINK

More>

浏览量

887

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi Decoction (泄浊除痹方)

Effects ofRheum officinale on the renal hypertrophy and hyperfiltration in the streptozotocin-induced diabetic rats

Curcumin reduces cardiac fibrosis by inhibiting myofibroblast differentiation and decreasing transforming growth factor β1 and matrix metalloproteinase 9 / tissue inhibitor of metalloproteinase 1

Saeng-Kankunbi-Tang (生肝健脾汤) protects liver against oxidative damage through activation of ERK/Nrf2 pathway

Role of heteroplasmic mutations in the mitochondrial genome and the ID4 gene promoter methylation region in the pathogenesis of chronic aplastic anemia in patients suffering from Kidney yin deficiency